Insulet (PODD) Competitors

Insulet logo
$145.29 -7.19 (-4.72%)
Closing price 04:00 PM Eastern
Extended Trading
$147.18 +1.90 (+1.30%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

PODD vs. GEHC, RMD, DXCM, PHG, and STE

Should you buy Insulet stock or one of its competitors? Insulet's main competitors and comparable companies include GE HealthCare Technologies (GEHC), ResMed (RMD), DexCom (DXCM), Koninklijke Philips (PHG), and STERIS (STE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Insulet compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

GE HealthCare Technologies has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Insulet has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Insulet has a net margin of 13.44% compared to GE HealthCare Technologies' net margin of 9.96%. Insulet's return on equity of 31.76% beat GE HealthCare Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
GE HealthCare Technologies9.96% 20.45% 5.97%
Insulet 13.44%31.76%14.48%

GE HealthCare Technologies currently has a consensus price target of $82.17, indicating a potential downside of 1.02%. Insulet has a consensus price target of $185.67, indicating a potential upside of 21.76%. Given Insulet's higher possible upside, analysts plainly believe Insulet is more favorable than GE HealthCare Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GE HealthCare Technologies
0 Sell rating(s)
11 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.52
Insulet
1 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.44

GE HealthCare Technologies has higher revenue and earnings than Insulet. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GE HealthCare Technologies$20.63B1.82$2.08B$4.7417.51
Insulet$2.71B3.91$247.10M$6.1424.83

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, GE HealthCare Technologies and GE HealthCare Technologies both had 14 articles in the media. Insulet's average media sentiment score of 0.81 beat GE HealthCare Technologies' score of 0.68 indicating that Insulet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GE HealthCare Technologies
3 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insulet
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Insulet beats GE HealthCare Technologies on 9 of the 13 factors compared between the two stocks.

How does Insulet compare to ResMed?

Insulet (NASDAQ:PODD) and ResMed (NYSE:RMD) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$2.71B3.91$247.10M$6.1424.83
ResMed$5.65B5.96$1.52B$10.9821.82

Insulet has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, ResMed has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

55.0% of ResMed shares are owned by institutional investors. 0.4% of Insulet shares are owned by company insiders. Comparatively, 0.6% of ResMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Insulet had 4 more articles in the media than ResMed. MarketBeat recorded 14 mentions for Insulet and 10 mentions for ResMed. Insulet's average media sentiment score of 0.81 beat ResMed's score of 0.45 indicating that Insulet is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insulet
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ResMed
7 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Insulet presently has a consensus price target of $185.67, suggesting a potential upside of 21.76%. ResMed has a consensus price target of $253.69, suggesting a potential upside of 5.90%. Given Insulet's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insulet is more favorable than ResMed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet
1 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.44
ResMed
0 Sell rating(s)
11 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.39

ResMed has a net margin of 27.79% compared to Insulet's net margin of 13.44%. Insulet's return on equity of 31.76% beat ResMed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insulet13.44% 31.76% 14.48%
ResMed 27.79%26.42%19.43%

Summary

Insulet and ResMed tied by winning 8 of the 16 factors compared between the two stocks.

How does Insulet compare to DexCom?

DexCom (NASDAQ:DXCM) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

DexCom has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Insulet has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

DexCom has a net margin of 19.42% compared to Insulet's net margin of 13.44%. DexCom's return on equity of 37.77% beat Insulet's return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom19.42% 37.77% 15.98%
Insulet 13.44%31.76%14.48%

DexCom has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$4.66B6.67$836.30M$2.5532.68
Insulet$2.71B3.91$247.10M$6.1424.83

DexCom currently has a consensus price target of $95.50, indicating a potential upside of 14.60%. Insulet has a consensus price target of $185.67, indicating a potential upside of 21.76%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than DexCom.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
2 Hold rating(s)
24 Buy rating(s)
2 Strong Buy rating(s)
3.00
Insulet
1 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.44

97.8% of DexCom shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Insulet had 6 more articles in the media than DexCom. MarketBeat recorded 14 mentions for Insulet and 8 mentions for DexCom. DexCom's average media sentiment score of 0.96 beat Insulet's score of 0.81 indicating that DexCom is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
3 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insulet
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

DexCom beats Insulet on 13 of the 17 factors compared between the two stocks.

How does Insulet compare to Koninklijke Philips?

Insulet (NASDAQ:PODD) and Koninklijke Philips (NYSE:PHG) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Koninklijke Philips has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Koninklijke Philips, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insulet$2.71B3.91$247.10M$6.1424.83
Koninklijke Philips$20.17B1.48$1.01B$1.1725.91

Insulet has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market. Comparatively, Koninklijke Philips has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market.

Insulet has a net margin of 13.44% compared to Koninklijke Philips' net margin of 5.40%. Insulet's return on equity of 31.76% beat Koninklijke Philips' return on equity.

Company Net Margins Return on Equity Return on Assets
Insulet13.44% 31.76% 14.48%
Koninklijke Philips 5.40%14.86%6.20%

Insulet currently has a consensus target price of $185.67, indicating a potential upside of 21.76%. Given Insulet's stronger consensus rating and higher probable upside, equities research analysts clearly believe Insulet is more favorable than Koninklijke Philips.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insulet
1 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.44
Koninklijke Philips
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Insulet had 12 more articles in the media than Koninklijke Philips. MarketBeat recorded 14 mentions for Insulet and 2 mentions for Koninklijke Philips. Insulet's average media sentiment score of 0.81 beat Koninklijke Philips' score of 0.00 indicating that Insulet is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insulet
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Koninklijke Philips
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Insulet beats Koninklijke Philips on 12 of the 16 factors compared between the two stocks.

How does Insulet compare to STERIS?

STERIS (NYSE:STE) and Insulet (NASDAQ:PODD) are both large-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

94.7% of STERIS shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

STERIS presently has a consensus target price of $283.50, indicating a potential upside of 7.48%. Insulet has a consensus target price of $185.67, indicating a potential upside of 21.76%. Given Insulet's higher possible upside, analysts clearly believe Insulet is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Insulet
1 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.44

Insulet has a net margin of 13.44% compared to STERIS's net margin of 13.41%. Insulet's return on equity of 31.76% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS13.41% 14.80% 9.99%
Insulet 13.44%31.76%14.48%

In the previous week, Insulet had 2 more articles in the media than STERIS. MarketBeat recorded 14 mentions for Insulet and 12 mentions for STERIS. Insulet's average media sentiment score of 0.81 beat STERIS's score of 0.68 indicating that Insulet is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
7 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Insulet
5 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

STERIS has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.94B4.32$782.30M$8.4331.29
Insulet$2.71B3.91$247.10M$6.1424.83

STERIS has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, Insulet has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Summary

STERIS and Insulet tied by winning 8 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Sign up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PODD vs. The Competition

MetricInsuletHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$10.36B$5.95B$7.85B$12.17B
Dividend YieldN/A1.69%2.46%4.41%
P/E Ratio23.6636.0532.4327.22
Price / Sales3.725.448.575.73
Price / Cash23.6123.9521.9322.50
Price / Book6.384.374.403.70
Net Income$247.10M$143.12M$3.52B$392.17M
7 Day Performance-3.02%-4.86%-5.34%-4.53%
1 Month Performance2.97%-2.87%-3.61%-5.86%
1 Year Performance-56.33%-0.76%0.01%-7.78%

Insulet Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PODD
Insulet
4.3926 of 5 stars
$145.29
-4.7%
$185.67
+27.8%
-54.2%$10.36B$2.71B23.665,400
GEHC
GE HealthCare Technologies
3.8159 of 5 stars
$84.03
+2.0%
$80.87
-3.8%
+13.5%$38.80B$20.63B17.7354,000
RMD
ResMed
4.4362 of 5 stars
$235.53
+0.1%
$253.69
+7.7%
-2.1%$33.83B$5.65B20.8611,370
DXCM
DexCom
3.7763 of 5 stars
$81.07
+2.1%
$95.50
+17.8%
+43.5%$33.00B$4.66B31.7911,000
PHG
Koninklijke Philips
2.5073 of 5 stars
$30.79
+1.5%
N/A+5.9%$30.53B$20.17B15.5365,340

Related Companies and Tools


This page (NASDAQ:PODD) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners